Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Published: Sep, 2016 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Review, H2 2016', provides in depth analysis on Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted pipeline therapeutics. 

The report provides comprehensive information on the Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) 
- The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Overview 7
Therapeutics Development 8
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Stage of Development 8
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Therapy Area 9
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Indication 10
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Companies 13
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Products under Development by Universities/Institutes 15
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 20
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Companies Involved in Therapeutics Development 21
Amgen Inc. 21
Bristol-Myers Squibb Company 22
Chong Kun Dang Pharmaceutical Corp. 23
Japan Tobacco Inc. 24
Kowa Company, Ltd. 25
Merck & Co., Inc. 26
Pfizer Inc. 27
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Drug Profiles 28
AMG-899 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
anacetrapib - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
BMS-795311 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
CKD-519 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
dalcetrapib - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
HL-16 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
K-312 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
PF-04445597 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Dormant Projects 41
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Discontinued Products 42
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) - Featured News & Press Releases 45
Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial 45
Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics 45
Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial 46
Nov 13, 2015: Merck Provides Update on REVEAL Outcomes Study 48
Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery 48
Jun 03, 2015: Dezima Pharma's CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet 49
Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease 50
Nov 13, 2014: Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein(a) Levels 50
Aug 29, 2014: Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia 51
Jul 08, 2014: Dezima Pharma extends clinical development program for its CETP Inhibitor TA-8995 52
Jan 13, 2014: Dezima Pharma Completes Patient Enrolment for TULIP Phase 2B Study with CETP Inhibitor TA-8995 52
Aug 29, 2013: Dezima Pharma initiates Phase 2b TULIP study on CETP inhibitor program DEZ-001 53
Nov 05, 2012: Roche's Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds 54
Aug 26, 2012: Merck Provides Update On Anacetrapib Development Program 55
May 07, 2012: Roche Provides Update On Phase III Study Of Dalcetrapib 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Amgen Inc., H2 2016 21
Pipeline by Bristol-Myers Squibb Company, H2 2016 22
Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 23
Pipeline by Japan Tobacco Inc., H2 2016 24
Pipeline by Kowa Company, Ltd., H2 2016 25
Pipeline by Merck & Co., Inc., H2 2016 26
Pipeline by Pfizer Inc., H2 2016 27
Dormant Projects, H2 2016 41
Discontinued Products, H2 2016 42
Discontinued Products (Contd..1), H2 2016 43
Discontinued Products (Contd..2), H2 2016 44